[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632906":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":34,"centralContacts":38,"locations":45,"responsibleParty":211,"collaborators":43,"id":213,"slug":43,"hasResults":214,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":43,"eligibilityCriteria":218,"healthyVolunteers":214,"sex":219,"minAge":220,"maxAge":43,"enrollmentInfo":221,"targetDuration":43,"studyType":224,"phases":225,"briefSummary":228,"conditions":229,"keywords":43,"overallStatus":48,"whyStopped":43,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":242},{"fullName":5,"class":6},"Merck Sharp & Dohme LLC","INDUSTRY",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm 1: Follicular Lymphoma (FL) MK-1045 Monotherapy Dose Optimization","EXPERIMENTAL","Participants will receive Dosage A of MK-1045 by Intravenous (IV) infusion for up to approximately 1 year of treatment or until discontinuation.",[13],"Biological: MK-1045",{"label":15,"type":10,"description":16,"interventionNames":17},"Arm 2: FL MK-1045 Longer Dosing Interval","Participants will receive Dosage B of MK-1045 by Intravenous (IV) infusion for up to approximately 1 year of treatment or until discontinuation.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Arm 3: FL MK-1045 Subcutaneous Administration","Participants will receive Dosage C of MK-1045 by subcutaneous (SC) injection for up to approximately 1 year of treatment or until discontinuation.",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Arm 4: Diffuse Large B-cell Lymphoma (DLBCL) MK-1045 Monotherapy Dose Optimization","Participants will receive Dosage D of MK-1045 by Intravenous (IV) infusion for up to approximately 1 year of treatment or until discontinuation.",[13],[27],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"BIOLOGICAL","MK-1045","Intravenous (IV) Infusion or Subcutaneous (SC) injection",[9,15,19,23],[33],"CN-201",[35],{"name":36,"affiliation":5,"role":37},"Medical Director","STUDY_DIRECTOR",[39],{"name":40,"role":41,"phone":42,"phoneExt":43,"email":44},"Toll Free Number","CONTACT","1-888-577-8839",null,"Trialsites@msd.com",[46,63,77,90,99,111,123,137,151,164,177,189,198],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Sanatorio Nuestra Senora del Rosario ( Site 1403)","RECRUITING","Rosario","Santa Fe Province","2001","Argentina",{"type":54,"coordinates":55},"Point",[56,57],-60.63932,-32.94682,{"lat":57,"lon":56},[60],{"name":61,"role":41,"phone":62,"phoneExt":43,"email":43},"Study Coordinator","+5493416149225",{"facility":64,"status":48,"city":65,"state":66,"zip":67,"country":68,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"Beijing Cancer hospital ( Site 1701)","Beijing","Beijing Municipality","100142","China",{"type":54,"coordinates":70},[71,72],116.39723,39.9075,{"lat":72,"lon":71},[75],{"name":61,"role":41,"phone":76,"phoneExt":43,"email":43},"+86 010-88196922",{"facility":78,"status":48,"city":79,"state":43,"zip":80,"country":81,"cosmosGeoPoint":82,"geoPoint":86,"contacts":87},"Shaare Zedek Medical Center ( Site 0603)","Jerusalem","9103102","Israel",{"type":54,"coordinates":83},[84,85],35.21633,31.76904,{"lat":85,"lon":84},[88],{"name":61,"role":41,"phone":89,"phoneExt":43,"email":43},"+972544922952",{"facility":91,"status":48,"city":79,"state":43,"zip":92,"country":81,"cosmosGeoPoint":93,"geoPoint":95,"contacts":96},"Haddasah Medical Center ( Site 0600)","9112001",{"type":54,"coordinates":94},[84,85],{"lat":85,"lon":84},[97],{"name":61,"role":41,"phone":98,"phoneExt":43,"email":43},"+972539101736",{"facility":100,"status":48,"city":101,"state":43,"zip":102,"country":81,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"Sheba Medical Center ( Site 0601)","Ramat Gan","5265601",{"type":54,"coordinates":104},[105,106],34.81065,32.08227,{"lat":106,"lon":105},[109],{"name":61,"role":41,"phone":110,"phoneExt":43,"email":43},"97235303030",{"facility":112,"status":48,"city":113,"state":43,"zip":114,"country":81,"cosmosGeoPoint":115,"geoPoint":119,"contacts":120},"Sourasky Medical Center. ( Site 0604)","Tel Aviv","6423906",{"type":54,"coordinates":116},[117,118],34.78057,32.08088,{"lat":118,"lon":117},[121],{"name":61,"role":41,"phone":122,"phoneExt":43,"email":43},"+97236974444",{"facility":124,"status":48,"city":125,"state":126,"zip":127,"country":128,"cosmosGeoPoint":129,"geoPoint":133,"contacts":134},"Istituto di Candiolo - IRCCS ( Site 0701)","Candiolo","Piedmont","10060","Italy",{"type":54,"coordinates":130},[131,132],7.59812,44.95858,{"lat":132,"lon":131},[135],{"name":61,"role":41,"phone":136,"phoneExt":43,"email":43},"+390119933355",{"facility":138,"status":48,"city":139,"state":140,"zip":141,"country":142,"cosmosGeoPoint":143,"geoPoint":147,"contacts":148},"Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Chłonnego ( Site 0900)","Warsaw","Masovian Voivodeship","02-781","Poland",{"type":54,"coordinates":144},[145,146],21.01178,52.22977,{"lat":146,"lon":145},[149],{"name":61,"role":41,"phone":150,"phoneExt":43,"email":43},"+48225462000",{"facility":152,"status":48,"city":153,"state":154,"zip":155,"country":142,"cosmosGeoPoint":156,"geoPoint":160,"contacts":161},"Pratia Onkologia Katowice ( Site 0902)","Katowice","Silesian Voivodeship","40-519",{"type":54,"coordinates":157},[158,159],19.02173,50.2597,{"lat":159,"lon":158},[162],{"name":61,"role":41,"phone":163,"phoneExt":43,"email":43},"+48501714019",{"facility":165,"status":48,"city":166,"state":43,"zip":167,"country":168,"cosmosGeoPoint":169,"geoPoint":173,"contacts":174},"Hospital Universitari Vall de Hebron ( Site 1102)","Barcelona","08035","Spain",{"type":54,"coordinates":170},[171,172],2.15899,41.38879,{"lat":172,"lon":171},[175],{"name":61,"role":41,"phone":176,"phoneExt":43,"email":43},"+34 932746000",{"facility":178,"status":48,"city":179,"state":43,"zip":180,"country":168,"cosmosGeoPoint":181,"geoPoint":185,"contacts":186},"Hospital Universitario Gregorio Maranon ( Site 1101)","Madrid","28007",{"type":54,"coordinates":182},[183,184],-3.70256,40.4165,{"lat":184,"lon":183},[187],{"name":61,"role":41,"phone":188,"phoneExt":43,"email":43},"+34915868888",{"facility":190,"status":48,"city":179,"state":43,"zip":191,"country":168,"cosmosGeoPoint":192,"geoPoint":194,"contacts":195},"Hospital Universitario 12 de Octubre ( Site 1105)","28041",{"type":54,"coordinates":193},[183,184],{"lat":184,"lon":183},[196],{"name":61,"role":41,"phone":197,"phoneExt":43,"email":43},"+34917792809",{"facility":199,"status":48,"city":200,"state":43,"zip":201,"country":202,"cosmosGeoPoint":203,"geoPoint":207,"contacts":208},"The Christie NHS Foundation Trust ( Site 1300)","Manchester","M20 4BX","United Kingdom",{"type":54,"coordinates":204},[205,206],-2.23743,53.48095,{"lat":206,"lon":205},[209],{"name":61,"role":41,"phone":210,"phoneExt":43,"email":43},"+4401614468201",{"type":212,"investigatorFullName":43,"investigatorTitle":43,"investigatorAffiliation":43,"oldNameTitle":43,"oldOrganization":43},"SPONSOR","100632906",false,"NCT07519772","A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)","A Phase 1b\u002F2 Study to Evaluate the Safety and Efficacy of MK-1045 Monotherapy or in Combination With Other Anticancer Agents in Participants With Non-Hodgkin Lymphoma","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Has disease that has relapsed (disease progression after remission) or is refractory (failure to achieve complete or partial response) to at least 2 prior systemic lines of therapy.\n* Has a histologically confirmed diagnosis of follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL).\n* DLBCL participants only: has progressed after or is ineligible for transplant and chimeric antigen receptor T (cell) (CAR-T) therapy.\n* Has provided tumor tissue sample (archival or newly obtained, if performed per standard of care).\n* Has documented retained expression of cluster of differentiation 19 (CD19) in tumor tissue obtained by biopsy after disease progression on CD19-targeting therapy, if experienced disease progression after prior CD19-targeting therapy.\n* Has well-controlled human immunodeficiency virus (HIV) on antiretroviral therapy if has a history of HIV infection.\n* Has undetectable hepatitis B virus (HBV) viral load and received and will continue to receive HBV antiviral therapy if hepatitis B surface antigen (HBsAg)-positive.\n* Has undetectable hepatitis C virus (HCV) viral load and received HCV antiviral therapy if has a history of HCV infection.\n* Has radiographically measurable disease per Lugano Response Criteria.\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has received a solid organ transplant.\n* Had or has clinically relevant central nervous system (CNS) diseases.\n* Has a history of serious cardiovascular or cerebrovascular diseases.\n* Had prior allogenic stem cell transplantation with acute graft-versus-host-disease (GVHD); has ongoing evidence of chronic GVHD manifesting as skin involvement, diarrhea, or increased serum bilirubin; or requires systemic immunosuppression for GVHD.\n* Is HIV-infected with a history of Kaposi's sarcoma and\u002For Multicentric Castleman's Disease.\n* Has received a live or live-attenuated vaccine within 30 days of randomization.\n* Has received prior CAR-T therapy within 3 months before the first dose of the study intervention.\n* Has a known additional malignancy that is progressing or required active treatment within the past 2 years.\n* Has known active CNS lymphoma or involvement.\n* Has active autoimmune disease that required systemic treatment in the past 2 years.\n* Has active infection requiring systemic therapy.\n* Has a history of severe bleeding disorders.\n* Has not recovered from major surgery or has ongoing surgical complications.\n* Has diagnosis of primary mediastinal B-cell lymphoma.","ALL","18 Years",{"count":222,"type":223},200,"ESTIMATED","INTERVENTIONAL",[226,227],"PHASE1","PHASE2","Researchers are looking for new ways to treat 2 types of non-Hodgkin lymphoma (NHL) called follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). FL is a slow-growing type of NHL. DLBCL is a fast-growing type of NHL. NHL is a cancer in the lymphatic system that causes swollen lymph nodes. The lymphatic system is part of the immune system.\n\nIn this study, researchers want to learn if MK-1045 can treat FL and DLBCL. MK-1045 is a study treatment that is an immunotherapy, which helps the immune system fight cancer.\n\nThe goals of this study are to learn how safe MK-1045 is and if people tolerate it. Researchers also want to see if FL and DLBCL respond (the cancer gets smaller or goes away) to treatment.",[230,231,232],"Lymphoma, Non-Hodgkin","Lymphoma, Follicular","Lymphoma, Large B-Cell, Diffuse","2026-07-01",{"date":235,"type":236},"2026-07-02","ACTUAL",{"date":238,"type":236},"2026-05-03",{"date":240,"type":223},"2031-04-01",{"name":5,"class":6},13]